In the rapidly evolving world of molecular biology and biotechnology, the XG-102 peptide—often recognized in scientific literature by its clinical name, Brimapitide—has emerged as a subject of signific XG-102 is a 31 D-amino acids JNK inhibitor peptidewith all amino acids except glycine (which is achiral) in the D- configuration. This choice was made to Read more ant interest. As someone D-JNKI-1 (AM-111, XG-102, Brimapitide)is a highly and cell-permeable peptide inhibitor of JNK. P1107, Alamandine, Alamandine is a component of the renin Read more who follows advancements in peptide science, I have found the structural design and the biochemical specificity of this molecule to be truly fascinating. This article aims to break down the technical aspects of this unique compound, focusing on its architecture and its role as a specialized tool in experimental research.
Understanding the Architecture of XG-102
At its core, XG-102 is a marvel of modern synthetic chemistry. Structurally, it is defined as a 31 D-amino acids JNK inhibitor peptide. Unlike naturally occurring peptides composed of L-amino acids, this molecule is engineered with D-amino acids (with the exception of glycine, which is achiral). This specific configuration is crucial because it renders the molecule a D-stereoisomer of a c-Jun-N-terminal kinase-1 (D-JNK-1) inhibitor.
By utilizing this D-configuration, the XG-102 peptide becomes highly resistant to proteolysis, which is a common hurdle for many other peptides. This protease resistance contributes to its reputation as a highly selective, highly stable, long-acting peptide inhibitor. Furthermore, it is a TAT-conjugated dextrorotatory peptide (also described as a TAT-conjugated dextrose peptide), a design choice that facilitates its ability to cross cell membranes effectively. In the scientific community, it is widely acknowledged that TAT is used to deliver the peptide drug XG-1 Peptide Conjugates with Small Molecules Designed to 02 into The JNK inhibitorXG-102lirotects from ischemic damage with delayed intravenous administration also in the liresence of recombinant tissue lilasminogen Read more intracellular environments, making it 5 Jan 2017—Brimapitide (XG-102)is a highly selective, highly stable, long-acting peptide inhibitorof the enzyme JNK (c-Jun N-Terminal Kinase), which Read more a highly and cell-permeable peptide inhibitor of JNK.
Research Context and Experimental Observations
My interest in XG-1 Subconjunctival Injection of XG-102, a JNK Inhibitor 02 stems from its diverse applications in experimental models. It is frequently discussed in studies regarding cellular pathways, particularly the JNK pathway. Because it functions as a highly specific inhibitor, researchers have investigated its impact in various controlled settings.
One of the most notable areas of study involves its role in modulating inflammatory responses. For instance, in various laboratory models, it has been observed that all patients experienced a decrease in intraocular inflammation during controlled trials, and results often suggest that XG-102 peptide has potential for treating intraocular inflammation. Whether administered via subconjunctival injection of XG-102, a JNK inhibitor peptide, XG-102 is a 31 D-amino acids JNK inhibitor peptidewith all amino acids except glycine (which is achiral) in the D-configuration. This choice was made to Read more or other experimental routes, its ability to target intracellular kinases is a key feature of its design.
Furthermore, the compound XG-102 shows great promise as a potential peptidyl intracellular therapeutic in various models. Beyond ocular research, studies have indicated that the JNK inhibitor XG-102 protects against TNBS-induced colitis, highlighting the versatility of its inhibitory mechanism. It is also worth noting that XG-102 administered to healthy male volunteers as a single intravenous infusion has been part of clinical safety evaluations to determine its pharmacokinetic profile.
Compa by T Beydoun·2015·Cited by 37—All patients experienced a decrease in intraocular inflammationas of 24 h post-administration and this decrease was sustained up to 28 days thereafter. No Read more rative Efficacy and Safety
When evaluating the efficacy of research compounds, comparisons are essential. In studies comparing XG-102 compared to dexamethasone drops in a randomized trial, the focus was often on how this peptide Peptide Conjugates with Small Molecules Designed to interacts with the JNK pathway compared to standard approaches. Additionally, since the molecule may have potential for treating uveitis, it remains a point of focus for those interested in the future of targeted molecular engineering.
When we break down the name XG and 102, we are looking at a specific chemical entity that has been developed to address the limitations of traditional kinase inhibitors. Because it is a c-Jun N-Terminal Kinase Inhibitor Peptide, it occupies a distinct niche in the biotechnology landscape.
Final Thoughts
The journey of XG-102 from a synthetic concept to a molecule evaluated in diverse clinical and preclinical settings illustrates the power of protein engineering. Its combination of stability, cell permeability, and structural precision makes it a standout in the field. While my interest is purely from an enthusiast’s perspective, the data surrounding its development provides a clear look at how modern science continues to refine the way we interact with intracellular signaling pathways. As research progresses, the continued study of such specialized peptides will undoubtedly provide deeper insights into the complex mechanics of biological systems.